Review
The aim of this review is to investigate the role of treatment beyond progression and locoregional approaches in BRAF-mutated metastatic melanoma and provide oncologists dealing with this malignancy a useful road map on when and why to choose this strategy.
Case Report
This case study covers a patient who received dabrafenib and trametinib and developed vitiligo-like depigmentation after treatment cessation.
Review
This review discusses the role of hematopoietic stem cell transplantation (HCT) and chimeric antigen receptor (CAR) T-cell therapy in DHL, as well as the role of potential novel agents such as BCL2 inhibitors, checkpoint inhibitors, bromodomain and extraterminal (BET) family inhibitors, Pi3K inhibitors, and others.
Review
A novel class of targeted therapy has been approved for patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer. There are currently three approved agents, which are oral cyclin-dependent kinase 4/6 (CDK4/6) inhibitors. In this review, all available data is summarized, unanswered questions are highlighted, and pharmacological differences between each CDK4/6 inhibitor are discussed.
Review
This article reviews the cutaneous side effects of main molecularly targeted cancer therapies for solid tumors.